Salarius amends merger fixing 14.1% legacy ownership; Nasdaq delisting risk from $2.5M equity shortfall

Decoy Therapeutics Inc.

Amendment eliminates cash-based exchange ratio adjustment; legacy Salarius stockholders retain 14.1%, Decoy holders 85.9% of combined company.
Nasdaq notified Salarius on March 26, 2025 it fails minimum $2.5M stockholders' equity for continued listing.
Company must submit a compliance plan by May 12, 2025; if accepted, Nasdaq may grant up to 180 days to regain compliance.
If plan rejected or compliance not regained, Nasdaq may delist; Salarius can request a hearing for up to 180 additional days.

item 1.01 item 3.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001615219-25-000040
form_type: 8-K
ticker: DCOY
cik: 0001615219
company_name: Decoy Therapeutics Inc.
filed_at: 2025-03-28T23:59:59+00:00
discovered_at: 2026-05-14T18:03:04.197380+00:00
generated_at: 2026-05-24T03:05:05.420986+00:00
sec_items: ["1.01", "3.01", "9.01"]
event_type: regulatory
sentiment: negative
materiality_score: 0.8
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001615219-25-000040
json_url: https://secwatch.observer/filing/0001615219-25-000040.json
markdown_url: https://secwatch.observer/filing/0001615219-25-000040.md
text_url: https://secwatch.observer/filing/0001615219-25-000040.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1615219/000161521925000040/0001615219-25-000040-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1615219/000161521925000040/flks-20250326.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001615219-25-000040

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.